Oragenics, Inc. Announces Notification of Noncompliance with Additional NYSE American Continued Listing StandardsBusiness Wire • Friday
Oragenics Appoints James Kelly MD, Chief Medical Officer, to Lead Phase II Clinical Trials for Treating ConcussionBusiness Wire • 03/18/24
Oragenics, Inc. Prepares Drug for Phase II Clinical Trials to Treat ConcussionBusiness Wire • 03/05/24
Oragenics, Inc. Announces Expiration of Its Investment Banking Engagement AgreementBusiness Wire • 02/07/24
Odyssey Health, Inc. Provides Update on Asset Purchase Agreement with Oragenics, Inc.Accesswire • 10/18/23
Oragenics Announces Appointment of Bruce Cassidy and John Gandolfo to Board of DirectorsBusiness Wire • 10/18/23
Oragenics to Acquire Odyssey Health's Neurological Drug Technology Pipeline Including Concussion Drug CandidateBusiness Wire • 10/05/23
Oragenics Enters into Agreement with Lantern Bioworks for Replacement-Therapy AssetsBusiness Wire • 09/29/23
Oragenics Project to Develop a Variant-Agnostic Protein Antigen for Use in its COVID-19 Intranasal Vaccine Receives Funding from CQDMBusiness Wire • 06/05/23
Oragenics Announces Positive Results in Several Lantibiotics Compounds Against MRSA and VREBusiness Wire • 03/14/23
Oragenics Appoints Janet Huffman as Chief Financial Officer Strengthening Executive Leadership TeamBusiness Wire • 03/08/23
Oragenics Enters into an Exclusive Global License Agreement with Inspirevax to Develop Intranasal Covid Vaccine CandidateBusiness Wire • 03/01/23